UH vaccine development could make you immune to COVID-19, experiments show

BySteven Devadanam, Houston CultureMap CultureMap logo
Wednesday, October 14, 2020
How will Houston handle COVID-19 vaccine distribution
In this related story from September, ABC13's Marla Carter shows the plan in place when COVID-19 vaccines are ready in Houston.

HOUSTON, Texas -- A major Houston university has taken a big leap in the race to battle debilitating diseases such as COVID-19. The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston-based biotech company developing novel vaccines against aggressive respiratory diseases such as coronavirus, according to a press release.

This means AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering. Varadarajan is a co-founder of AuraVax.

The vaccine is a nasal inhalant, much like FluMist. Based on pre-clinical experimentation, Varadarajan reports his technology not only elicits a mucosal immune response, but also systemic immunity, according to UH.

For more on this story, visit our partners at Houston CultureMap.

SEE ALSO: Most people try to avoid COVID-19. But thousands are signing up to be deliberately exposed

RELATED: White House rejects updated FDA guidelines on coronavirus vaccine approval